Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

NCBI PD cannot differentiate between serovar Albany and serovar Duesseldorf; additional genetic markers are required for in silico serotyping of serovar Albany. The link is still provided: https://www.ncbi.nlm.nih.gov/pathogens/isolates/#(taxgroup_name:%22Salmonella%20enterica%22)%20AND%20computed_types:(%22serotype=Albany%20or%20Duesseldorf%22)

Genetic characteristics: Serovar Albany has been found to be polyphyletic with two lineages identified. Ali et al. studied a total of 434 serovar Albany isolates and found a high proportion of Albany isolates demonstrated resistance to nalidixic acid (99.3%), trimethoprim/sulfamethoxazole (97.9%), ampicillin (86.6%), chloramphenicol (86.6%), and tetracycline (85.7%). Additionally, all isolates resistant to cefoxitin carried the CMY-2-type β-lactamase and was classified into seven unique pulsotypes, with the majority being types IV-b (43.75%) and IV-a (25%). In a Taiwanese study, among turkey isolates they included, 75.3% of Albany isolates (64/85) exhibited resistance to 6 or more antimicrobials. Another Taiwanese study stated that Albany strains carrying ICE_erm42 exhibited high-level resistance to azithromycin, and the element was capable of transferring to phylogenetically distant species, such as Vibrio cholerae, through conjugation.

...

Recalls: There have been no recent recalls linked to this serovar.

Relevant links:

  1. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1547190/full
  2. https://www.liebertpub.com/doi/10.1089/fpd.2023.0034
  3. https://www.sciencedirect.com/science/article/pii/S0032579119306182
  4. https://www.jstor.org/stable/23361445?seq=1
  5. https://journals.asm.org/doi/10.1128/aac.02634-20
  6. https://atlas.ecdc.europa.eu/public/index.aspx
  7. https://webgate.ec.europa.eu/rasff-window/screen/notification/568767
  8. https://webgate.ec.europa.eu/rasff-window/screen/notification/524670
  9. https://webgate.ec.europa.eu/rasff-window/screen/notification/513985